Pacira BioSciences Inc logo

PCRX

Pacira BioSciences Inc

$58.42

Earnings Summary

Revenue
$169.41Mn
Net Profits
$19.88Mn
Net Profit Margins
11.73%
PE Ratio
68.18

Highlights

Revenue:

Pacira BioSciences Inc’s revenue jumped 24.94% since last year same period to $169.41Mn in the Q2 2022. On a quarterly growth basis, Pacira BioSciences Inc has generated 7.23% jump in its revenue since last 3-months.

Net Profits:

Pacira BioSciences Inc’s net profit jumped 4.17% since last year same period to $19.88Mn in the Q2 2022. On a quarterly growth basis, Pacira BioSciences Inc has generated 191.1% jump in its net profits since last 3-months.

Net Profit Margins:

Pacira BioSciences Inc’s net profit margin fell -16.63% since last year same period to 11.73% in the Q2 2022. On a quarterly growth basis, Pacira BioSciences Inc has generated 171.47% jump in its net profit margins since last 3-months.

PE Ratio:

Pacira BioSciences Inc’s price-to-earnings ratio after this Q2 2022 earnings stands at 68.18.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Pacira BioSciences Inc post its latest quarter earnings

EPS Estimate Current Quarter
0.88
EPS Estimate Current Year
0.88

Highlights

EPS Estimate Current Quarter:

Pacira BioSciences Inc’s earning per share (EPS) estimates for the current quarter stand at 0.88 - a 6.02% jump from last quarter’s estimates.

EPS Estimate Current Year:

Pacira BioSciences Inc’s earning per share (EPS) estimates for the current year stand at 0.88.

Key Ratios

Key ratios of the Pacira BioSciences Inc post its Q2 2022 earnings

Earning Per Share (EPS)
0.51
Return on Assets (ROA)
0.05
Return on Equity (ROE)
0.05
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Pacira BioSciences Inc’s earning per share (EPS) fell -33.77% since last year same period to 0.51 in the Q2 2022. This indicates that the Pacira BioSciences Inc has generated -33.77% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Pacira BioSciences Inc’s return on assets (ROA) stands at 0.05.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Pacira BioSciences Inc’s return on equity (ROE) stands at 0.05.

Dividend Per Share (DPS):

Pacira BioSciences Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-08-03
0.88
0.51
-42.05%
2022-05-04
0.83
0.64
-22.89%

Company Information

Pacira BioSciences, Inc.is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. The company's long-acting local analgesic, EXPAREL ® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, Pacira acquired the iovera° system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves.

Organisation
Pacira BioSciences Inc
Headquarters
Parsippany, New Jersey, US
Employees
624
Industry
Health Technology